Navigation Links
Par Pharmaceutical Reports Third-Quarter 2007 Results
Date:12/20/2007

5 million, representing the premium paid, was charged to R&D in the third quarter.

Third-quarter selling, general and administrative (SG&A) expense decreased 15.3 percent to $33.9 million. The decrease in 2007 SG&A expense was primarily due to the non-recurrence of severance costs incurred in 2006 for executives of $7.1 million, partially offset by increased costs associated with the expansion of finance and accounting functions and increased professional costs related to the Company's restatement of prior periods.

2007 Financial Outlook

Par has adjusted its previously announced guidance for full-year 2007 earnings per diluted share of $1.45-$1.50 from $1.35-$1.50. Total net revenue is expected to be between $760-$780 million. SG&A is expected to be $130-$133 million, including approximately $2 million in severance costs. Research and development cost is projected to be in the range of $75-$80 million, including approximately $19 million in branded milestone payments. Total projected expenses for the full-year include approximately $18-20 million of share-based compensation and $24-$26 million of depreciation and amortization expenses. Adjusting for non-GAAP items highlighted on the summary of estimated operating results for full year 2007 at the end of this press release, full year earnings per diluted share is projected to be $1.50-$1.55.

Stock Repurchase Program

Since October 1, 2007, Par has repurchased 1,643,094 shares of its common stock at a total cost of $31.5 million. On September 28, 2007, Par announced that its Board of Directors had authorized the repurchase of up to $75 million of the Company's common stock.

Conference Call

Par has scheduled a conference call for Thursday, December 20, 2007 at 9:00 am EST to discuss results for the third quarter of 2007. Par invites investors and the general public to listen to a webcast of the conference call. Access to the live webcast can be made via the Company's webs
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... 18, 2013 The product liability attorneys at ... on behalf of consumers nationwide who have sustained serious tendon ... shoes. These cases are all part of MDL 2308 and ... lawsuits will be heard in the U.S. District Court ... Wright & Schulte, LLC specializes in defending the rights of ...
(Date:5/17/2013)... J. Schultz, D.D.S., is making the Laser Assisted New Attachment ... of San Juan Capistrano. The laser surgery disintegrates up ... a scalpel to cut the tissue away. The periodontist ... wavelengths to target the diseased tissue and bacteria while leaving ... in every hundred dental professionals is trained and authorized to ...
(Date:5/17/2013)... May 17, 2013 Stryker hip lawsuit ... year’s Rejuvenate and ABG II Modular-Neck Hip Stem recall continue ... LLP reports. According to court documents, a Case Management ... May 15th, at which time the Court, among other things, ... the litigation must submit Fact Sheets to Defendant and Liaison ...
(Date:5/17/2013)... 17, 2013 Charlotte’s top professional athletes ... with children served by the Muscular Dystrophy Association at ... Tuesday, May 21 at Bank of America Stadium from ... unique social event that pairs top professional athletes and ... an “MDA Buddy” (a local child living with a ...
(Date:5/17/2013)... 2013 Parker Waichman LLP , ... of victims injured by defective medical devices, notes that ... in a May 16, 2013, statement that ... ceramic-on-metal hip replacement products; specifically, the metal liners in ... Hip System will no longer be available worldwide after ...
Breaking Medicine News(10 mins):Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 2Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 3Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 4Health News:San Clemente, CA Periodontist, Dr. Allen J. Schultz, Now Provides Laser Gum Disease Treatment to Southern Orange County Periodontal Disease Patients 2Health News:Stryker Hip Lawsuit News: Bernstein Liebhard LLP Reports on Recent Case Management Conference in New Jersey Stryker Hip Recall Litigation 2Health News:Stryker Hip Lawsuit News: Bernstein Liebhard LLP Reports on Recent Case Management Conference in New Jersey Stryker Hip Recall Litigation 3Health News:MDA Hosts Annual Charlotte Muscle Team Event 2Health News:MDA Hosts Annual Charlotte Muscle Team Event 3Health News:Parker Waichman LLP Responds to Johnson & Johnson’s Decision to Discontinue Some of Its DePuy All-metal and Ceramic-on-metal Hip Implant Products 2Health News:Parker Waichman LLP Responds to Johnson & Johnson’s Decision to Discontinue Some of Its DePuy All-metal and Ceramic-on-metal Hip Implant Products 3
... continued to pay for sex despite having steady partners, according to ... to visiting prostitutes recently while 27 percent admitted that it was ... paying for sex were in a concurrent relationship," said Dr Tamsin ... sex while at home or abroad, but used condoms in most ...
... infamous for food poisoning that kills hundreds of ... into and multiply inside macrophages, the very immune ... and destroy invading microbes. ,Just how ... to prey complicit in promoting infection, has seemed ...
... the University of Michigan Health System finds that treating ... alpha blocker has many benefits// and can even allow ... the US, the disease affects 13 percent of men ... by minimally invasive surgery, but research suggests that medicines ...
... of public health interventions can cost hundreds of lives, especially ... if the science is good, we should act before the ... required before new interventions are implemented. But in 2003, the ... parachutes to show that situations still exist where such trials ...
... Loma Linda University (LLU) shows that adding just a handful ... oxidation of blood lipids// , thus helping reduce the risk ... in part due to the pecan’s significant content of vitamin ... of phytochemicals that can have a unique effect on the ...
... stress syndrome, better known as shin splints, in distance runners ... in Messina, Italy. ,According to the study, medial ... injuries that may be found in athletes and accounts for ... ,For the study, high-resolution CT of both tibiae (shin bones) ...
Cached Medicine News:Health News:An Infectious Agent of Deception, Exposed Through Proteomics 2Health News:Drugs May Help Urinary Disease 2Health News:Antioxidant-Rich Pecans Protect Against Unhealthy Oxidation in the Body 2
(Date:5/17/2013)... 17, 2013  Atossa Genetics, Inc. (NASDAQ: ATOS ... Kyle Guse , Chief Financial Officer & General Counsel, ... on Thursday, May 30, 2013, in New York ... The Company,s presentation is scheduled to begin at 3:30 ... To access the webcast, go to www.atossagenetics.com . ...
(Date:5/17/2013)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ( http://www.oramed.com ... today that the United States Food and Drug Administration ... for ORMD-0801, its oral insulin capsule. "We ... proceed," stated Nadav Kidron , CEO ... for Oramed and we look forward to continuing to ...
(Date:5/17/2013)... NATICK, Mass. , May 17, 2013  Boston ... to participate at the annual EuroPCR Scientific Program May ... "We are pleased to present a particularly rich and ... Keith Dawkins , M.D., global chief ... several trials will be presented, including the NG PROMUS ...
Breaking Medicine Technology:Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8
... Worldwide, Inc. (NYSE: OWW ) will host a conference call to discuss the ... Wednesday, May 5, 2010 at 10:00 a.m. EDT ( 9:00 a.m. CDT ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20070813/AQM125LOGO ) , ... A live webcast of the call can be accessed through the Orbitz Worldwide Investor Relations ...
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a biopharmaceutical company ... Paul F. Truex , Anthera,s President and Chief Executive Officer will present ... MA on Monday, May 3, 2010 at approximately ... , , ...
Cached Medicine Technology:Orbitz Worldwide, Inc. to Host First Quarter 2010 Earnings Call on May 5 2Orbitz Worldwide, Inc. to Host First Quarter 2010 Earnings Call on May 5 3Anthera Pharmaceuticals to Present at Deutsche Bank Securities' 35th Annual Health Care Conference 2
Rubella IgG II ELISA....
The Urine Legionella Antigen ELISA kit detects the presence of Legionella pneumophila serogroup1 antigen in urine....
Mumps IgG ELISA....
Measles IgG ELISA....
Medicine Products: